“This study is one of the first studies to use olaparib tablets instead of olaparib capsules,” said Saul Rivkin, MD, founder and chairman of the Marsha Rivkin Center for Ovarian Cancer Research, and a research scientist at the Swedish Cancer Institute, both in Seattle, Washington. “The goal was to find the maximum tolerated dose of olaparib tablets plus weekly metronomic carboplatin and paclitaxel in patients with relapsed ovarian cancer.

Rivkin and colleagues enrolled 14 heavily pretreated ovarian cancer patients (from three to eight prior therapies), ages 42 to 77. Patients received paclitaxel and carboplatin weekly, three weeks out of four, with increasing doses of olaparib. The maximum tolerated dose of olaparib was found to be 150 mg twice daily for three consecutive days of each week of each cycle.

Of the 12 evaluable patients, four had a complete response (33 percent), four had a partial response (33 percent), two had stable disease (16 percent), and two had disease progression (16 percent).

Three patients with a complete response, three with a partial response, one with stable disease, and one with disease progression had BRCA mutations detected in their tumors.

The most common grade 3 toxicities included neutropenia, leukopenia, lymphopenia, and anemia. There was no evidence of gastrointestinal, renal, cardiac, hepatic, pulmonary, or dermatologic toxicities in any of the patients with a toxicity grade greater than 2.

The investigators plan to recruit up to 40 additional patients in the phase II extension of this protocol.

This study was funded by the Dulien Fund and AstraZeneca. Rivkin declares no conflicts of interest.

Please support this site with your donations—that's what keeps it going. Plus, if you donate just $25 you'll receive a copy of my book, Surviving Triple-Negative Breast Cancer. Click the Donate button on the right to donate through PayPal. You'll then get an email from me asking if you want the book, how you want it signed and where you want it sent. And if you just want to donate without receiving the book, that's wonderful. Thanks! And hugs.

No comments:

DONATE

Please help support this blog. All donations go to time and resources to maintain this rich source of information about triple-negative breast cancer.

Donate in the name of a friend or family member with breast cancer and I'll send a personal note of encouragement to her or him.

NOTE: I am all out of books, so I can no longer send them as part of the donation.

Surviving Triple-Negative Breast Cancer: Hope, Treatment, Recovery

Finally! A book about TNBC written by a woman who's been through it—Patricia Prijatel, founder and editor of this blog. If you like this blog, you'll love this book.

Patricia Prijatel

Founder of Positives About Negative and author of Surviving Triple Negative Breast Cancer

Top Cancer Blog

From Symphony Sisterhood

Welcome

When I was diagnosed with hormone-receptor-negative breast cancer, I required a positive attitude of myself—I was not going to let a disease have the upper hand. I hope I can share some at that attitude with you while I offer what I have learned in my trek through this disease as a patient and medical writer.

It's a given that life ends in death. Cancer just makes you face that inevitability more directly than you might have before. To me, that means living fully right now.

Three Mountain Dogs, a children's book by Patricia Prijatel

Triple-negative breast cancer (TNBC) lacks hormone receptors for estrogen, progesterone, and Her2/neu. It affects about 20 percent of all those with breast cancer. This blog offers information and hope for those with TNBC and other forms of hormone-negative breast cancer.

Calm Spirit Note Cards

Blank greeting cards with the Calm Spirit image are available in packets of 6. They're ideal for sending a personal message of encouragement to anyone living with cancer. Boxes of six are available for $10.00 and can be ordered by contacting my friend Madlyn at madlyn.ferraro@ gmail com. Individual cards are $2.50 each.